Abstract
The anthracycline antibiotic adriamycin is a highly effective anticancer chemotherapeutic agent (Blum and Carter, 1974). Its clinical use is limited to a total dose of 550 mg/sq m body surface by cumulative cardiotoxicity (Lefrak et al., 1973). As there is no reliable in vitro-test system for the cardiotoxicity of new anthracyclines pathological and electrocardiographical evaluations in mouse, rat, and rabbit are mainly used (Zbinden and Brändle, 1975; Mettler et al., 1977).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bachur, N., Gordon, S., and Gee, M., 1977, Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation, Mol.Pharmacol.,13:901-910.
Bachur, N.R., Gordon, S.L., and Gee, M.V., 1978, A general mechanism for microsomal activation of quinone anticancer agents to free radicals, Cancer Res., 38: 1745–1750.
Bachur, N.R., Gordon, S.L., Gee, M.V., and Kon, H., 1979, NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals, Proc.Natl.Acad.Sci.USA,76:954-957.
Bertazzoli, C., Sala, L., Bllerini, L., Watanabe, T., and Folkers, K., 1976, Effect of adriamycin on the activity of the succinate dehydrogenase-coenzyme Q10 reductase of the rabbit myocardium, Res.Commun.Chem.Pathol.Pharm.,15:797 -800.
Blum, R.H., and Carter, S.K., 1974, Adriamycin: A new anticancer drug with significant clinical activity, Ann.Intern.Med., 80: 249–259.
Bolt, H.M., and Kappus, H., 1974, Irreversible binding of ethynyl-estradiol metabolites to protein and nucleic acids as catalyzed by rat liver microsomes and mushroom tyrosinase, J.Steroid.Biochem.,5:179-184.
Breed, J.G.S., Zimmermann, A.N.E., Dormans, J.A.M.A., and Pinedo, H.M., 1980, Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit, Cancer stes., 40: 2033–2038.
Burton, G.M.; Henderson, C.A., Balcerzak, S.P., and Sagone, Jr., A.L., 1979, Effect of adriamycin on the metabolism of heart slices, Int.J.Radiation Oncology Biol.Phys.,5:1287-1289.
Byfield, J.E., 1977, Adriamycin cardiac toxicity: A different hypothesis, Cancer Treat.Rep., 61: 497–498.
Doroshow, J.H., and Reeves, J., 1980, A. nthracycline-enhanced oxygen radical formation in the heart, Proc.Amer.Ass.Cancer Res. A.er.Soc.Clin.Oncol.,21:266, abstr. 1067.
Goodman, J., and Hochstein, P., 1977, Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin, Biochem. Biophys.Res.Commun.,77:797–803.
Handa, K., and Sato, S., 1975, Generation of free radicals of quinone group-containing anticancer chemicals in an NADPH-microsome system as evidenced by initiation of sulfite oxidation, Gann, 66: 43–47.
Iwamoto, Y., Hansen, I.L., Porter, T.H., and Folkers, K., 1974, Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxi-dase by adriamycin and other quinones having antitumor activity, Biochem.Biophys.Res.Commun.,58:633–638.
Kishi, T., Watanabe, T., and Folkers, K., 1976, Bioenergetics in clinical medicine: Prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium, Proc.Natl.Acad.Sci.USA,73:4653–4656.
Lefrak, E.A., Ptha, J. Rosenheim, S. and Gottlieb, J.A., 1973, A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer, 32: 302–314.
Locker, G.Y., Doroshow, J.H., and Myers, C.E., 1977, Glutathione peroxidase: Its role in adriamycin cardiotoxicity, Proc.Amer. Ass.Cancer Res. Amer.Soc.Clin.Oncol.,18:87, abstr. 348.
Lown, J.W., Sim, S., Majumdar, K.C., and Chang, R.-Y., 1977, Strand scission of DNA by bound adriamycin and daunomycin in the presence of reducing agents, Biochem.Biophys.Res.Commun., 76: 705–710.
Lowry, 0.H., Rosenbrough, N.J., Farr, A.L., and Randall, R.J., 1951, Protein measurement with the Folin phenol reagent, J.Biol.Chem., 193: 265–275.
Lucacchini, A., Martini, C., Segnini, D., and Ronca, G., 1979, Evidence of soluble protein binding adriamycin by affinity chromatography, Experientia,35:1148–1149.
Mailer, K., and Petering, D.H., 1976, Inhibition of oxidative phosphorylation in tumor cells and mitochondria by daunomycin and adriamycin, Biochem.Pharmacol.,25:2085–2089.
Marco, A., 1975, Adriamycin (NSC-123127): Mode and mechanism of action, Cancer Chemotherapy Rep. Pt.3, 6: 91–106.
Mettler, FTP.,Young, D.M., and Ward, J.M., 1977, Adriamycin-induced cardiotoxicity (cardiopathy and congestive heart failure) in rats, Cancer Res.,37:2705–2713.
Mimnaugh, E.G., Siddik, Z.H., Drew, R., Sikic, B.I., and Gram, T.E., 1979, The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice, Toxicol. Appl.Pharmacol., 49: 119–126.
Momparler, R.L., Karon, M., Siegel, S.E., and Avila, F., 1976, Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free system and intact cells, Cancer Res., 36: 2891–2895.
Olson, H.M., and Capen, C.C., 1978, Chonic cardiotoxicity of doxorubicin in the rat: Morphologic and biochemical investigations, Toxicol.Appl.Pharmacol.,44:605–616.
Omura, T., and Takesue, S., 1970, A new method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes, J.Biochem.(Tokyo),67:249–257.
Reed, D.J., and Babson, J.R., 1980, Adriamycin-BCNU mediated plasma membrane leakage and loss of glutathione protection with normal and tumor cells, Proc.Amer.Ass.Cancer.Res. Amer.Soc. Clin.Oncol.,21:307, abstr. 1230.
Remmer, H., Greim, H., Schenkman, J.B., and Estabrook, R.W., 1967, Methods for the elevation of hepatic microsomal mixed function oxidase levels and cytochrome P450, Meth.Enzymol.,10:703–708.
Ross, W., 1980, Adriamycin-induced DNA double strand breaks, Proc. Amer.Ass.Cancer Res. Amer.SOc.Clin.Oncol.,21:274, abstr. 1100.
van Rossum, G.D.V., and Gosâlvez, M., 1976, Inhibition of ion-transport by the antitumour antibiotic adriamycin, Fed.Proc., 35: 3, 3201.
Schwartz, H.S., 1975, DNA breaks in P-288 tumor cells in mice after treatment with daunorubicin and adriamycin, Res.Commun. Chem. Path.Pharmacol.,10:51–64.
Scheulen, M., Wollenberg, P., Bolt, H.M., Kappus, H., and Remmer, H., 1975, Irreversible binding of dopa and dopamine metabolites to protein by rat liver microsomes, Biochem.Biophys.Res.Commun., 66: 1396–1400.
Taylor, D., and Hochstein, P., 1978, Inhibition by adriamycin of a metmyoglobin reductase from beef heart, Biochem.Pharmacol., 27: 2079–2082.
Yamanaka, N., Kato, T., Nishida, K., Fujikawa, T., Fukushima, M., and Ota, K., 1979, Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by (dl)-alpha-tocopheryl acetate or coenzyme Q10 in mouse, Cancer Chemother.Pharmacol., 3:223–227’.
Yasumi, M., Minaga, T., Takamura, K., Kizu, A., and Ijichi, H., 1980, Inhibition of cardiac NADP-linked isocitrate dehydrogenase by adriamycin, Biochem.Biophys.Res.Commun.,93:631–636.
Zbinden, G., and Brändle, E., 1975, Toxicology screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats, Cancer Chemotherapy Rep., 59: 707–715.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer Science+Business Media New York
About this chapter
Cite this chapter
Scheulen, M.E., Kappus, H. (1982). Metabolic Activation of Adriamycin by Nadph-Cytochrome P-450 Reductase, Rat Liver and Heart Microsomes and Covalent Protein Binding of Metabolites. In: Snyder, R., et al. Biological Reactive Intermediates—II. Advances in Experimental Medicine and Biology, vol 136. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-0674-1_36
Download citation
DOI: https://doi.org/10.1007/978-1-4757-0674-1_36
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4757-0676-5
Online ISBN: 978-1-4757-0674-1
eBook Packages: Springer Book Archive